Most modern cancer treatments involve induction of enzyme-dependent apoptosis in cancer cells. However, these cells have a great ability to develop resistance to treatment. Many of them can defend themselves against apoptosis, so scientists are still looking for ways to kill them.
In the future, viroptosis may become one of these approaches. It is an iron-dependent form of cell death characterized by the accumulation of lipid peroxides. We know that ferroptosis is genetically and biologically different from other types of cell death, but its detailed mechanisms remain unknown.
Ferrosclerosis is currently being studied not only for cancer treatment. Scientists are studying its role in the development of many pathological processes that occur in both Alzheimer’s disease and cardiovascular disease. We know that this mechanism is involved in these processes. This is partly because ferroptosis is still not well understood and is not expected to be used for treatment at this time. But maybe it will happen in the not too distant future.
Experts studying ferroptosis for the controlled induction of cancer cell death must confront several problems, including the fact that this mechanism is non-selective and kills many different cells located in the immediate vicinity of the cancer cell. A particular problem is that dendritic cells, T lymphocytes and neutrophils die.
However, scientists from the United States, China and France report that, after extensive research, they have found a promising molecule N6F11, which not only initiates the ferroptosis process, but also selectively catalyzes the degradation of the enzyme GPX4, which prevents ferroptosis. Even more surprising is the fact that N6F11 degrades GPX4 in pancreatic, bladder, breast and cervical cancer cells, while GPX4 does not damage – at least in cell cultures – dendritic cells, T lymphocytes and neutrophils.
Scientists from Columbia University, the University of Paris and UT Southwestern Medical Center conducted tests on mice with human pancreatic cancer and found that the animals underwent treatment without significant side effects. Scientists linked this to N6F11’s ability to stimulate T cells.
— Iron eye disease may become a new way to treat cancerous tumors. Unfortunately, the methods currently tested not only induce selective ferroptosis in cancer cells but also initiate it in immune cells, reducing the body’s defensive capabilities, says the study’s lead author, Jingbo Li of Central South University in China and the UT Center. Southwestern Medical. in the United States of America. We found a small molecule, N6F11, that stimulates selective degradation of GPX4 in cancer cells, but not in immune cells. In small tumors, N6F11-initiated ferroptosis leads to a strong anti-tumor response in the immune system, he adds. Search details can be found in: Science Translational Medicine.
Echo Richards embodies a personality that is a delightful contradiction: a humble musicaholic who never brags about her expansive knowledge of both classic and contemporary tunes. Infuriatingly modest, one would never know from a mere conversation how deeply entrenched she is in the world of music. This passion seamlessly translates into her problem-solving skills, with Echo often drawing inspiration from melodies and rhythms. A voracious reader, she dives deep into literature, using stories to influence her own hardcore writing. Her spirited advocacy for alcohol isn’t about mere indulgence, but about celebrating life’s poignant moments.
